Scientific Reports (Apr 2021)

Serum syndecan-1 reflects organ dysfunction in critically ill patients

  • Keiko Suzuki,
  • Hideshi Okada,
  • Kazuyuki Sumi,
  • Hiroyuki Tomita,
  • Ryo Kobayashi,
  • Takuma Ishihara,
  • Yoshinori Kakino,
  • Kodai Suzuki,
  • Naomasa Yoshiyama,
  • Ryu Yasuda,
  • Yuichiro Kitagawa,
  • Tetsuya Fukuta,
  • Takahito Miyake,
  • Haruka Okamoto,
  • Tomoaki Doi,
  • Takahiro Yoshida,
  • Shozo Yoshida,
  • Shinji Ogura,
  • Akio Suzuki

DOI
https://doi.org/10.1038/s41598-021-88303-7
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Syndecan-1 (SDC-1) is found in the endothelial glycocalyx and shed into the blood during systemic inflammatory conditions. We investigated organ dysfunction associated with changing serum SDC-1 levels for early detection of organ dysfunction in critically ill patients. To evaluate the effect of SDC-1 on laboratory parameters measured the day after SDC-1 measurement with consideration for repeated measures, linear mixed effects models were constructed with each parameter as an outcome variable. A total of 94 patients were enrolled, and 831 samples were obtained. Analysis using mixed effects models for repeated measures with adjustment for age and sex showed that serum SDC-1 levels measured the day before significantly affected several outcomes, including aspartate aminotransferase (AST), alanine transaminase (ALT), creatinine (CRE), blood urea nitrogen (BUN), antithrombin III, fibrin degradation products, and D-dimer. Moreover, serum SDC-1 levels of the prior day significantly modified the effect between time and several outcomes, including AST, ALT, CRE, and BUN. Additionally, increasing serum SDC-1 level was a significant risk factor for mortality. Serum SDC-1 may be a useful biomarker for daily monitoring to detect early signs of kidney, liver and coagulation system dysfunction, and may be an important risk factor for mortality in critically ill patients.